Celularity (CELUW) Total Non-Current Liabilities (2019 - 2025)
Celularity (CELUW) reported Total Non-Current Liabilities of $143.8 million for Q4 2025, up 19.29% year-over-year from $120.6 million in Q4 2024, and up 9.97% quarter-over-quarter from $130.8 million in Q3 2025.
Celularity (CELUW) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Celularity (CELUW) has 7 years of Total Non-Current Liabilities data on file, last reported at $143.8 million in Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $143.8 million, up 19.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $143.8 million (up 19.29% YoY), and the FY2025 annual result was $143.8 million, up 19.29% from the prior year.
- Total Non-Current Liabilities advanced to $143.8 million in Q4 2025 per CELUW's latest filing, from $130.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $342.4 million in Q1 2022 and troughed at $16.0 million in Q1 2021.
- A 5-year average of $134.7 million and a median of $123.0 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 2043.66% in 2022, then plunged 52.79% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $82.5 million in 2021, then gained by 16.65% to $96.2 million in 2022, then climbed by 6.67% to $102.6 million in 2023, then rose by 17.49% to $120.6 million in 2024, then climbed by 19.29% to $143.8 million in 2025.
- Business Quant data shows CELUW's Total Non-Current Liabilities at $143.8 million in Q4 2025, $130.8 million in Q3 2025, and $137.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Celularity | - | - | -3.27 Mn | 143.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 143.85 Mn |
| Sep 30, 2025 | 130.81 Mn |
| Jun 30, 2025 | 137.00 Mn |
| Mar 31, 2025 | 126.32 Mn |
| Dec 31, 2024 | 120.58 Mn |
| Sep 30, 2024 | 111.28 Mn |
| Jun 30, 2024 | 99.60 Mn |
| Mar 31, 2024 | 97.48 Mn |
| Dec 31, 2023 | 102.64 Mn |
| Sep 30, 2023 | 125.34 Mn |
| Jun 30, 2023 | 126.31 Mn |
| Mar 31, 2023 | 206.47 Mn |
| Dec 31, 2022 | 96.22 Mn |
| Sep 30, 2022 | 258.79 Mn |
| Jun 30, 2022 | 255.76 Mn |
| Mar 31, 2022 | 342.40 Mn |
| Dec 31, 2021 | 82.49 Mn |
| Sep 30, 2021 | 96.55 Mn |
| Jun 30, 2021 | 18.10 Mn |
| Mar 31, 2021 | 15.97 Mn |